InvestorsHub Logo
Followers 230
Posts 21490
Boards Moderated 2
Alias Born 08/03/2006

Re: None

Friday, 07/15/2022 9:45:15 AM

Friday, July 15, 2022 9:45:15 AM

Post# of 769
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $20
6:51 am ET July 1, 2022 (Benzinga) Print
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $18 to $20.

Latest Ratings for LXRX DateFirmActionFromTo

Jan 2021WedbushDowngradesOutperformNeutral Jan 2021JP MorganUpgradesUnderweightNeutral Dec 2020CitigroupUpgradesNeutralBuy

View More Analyst Ratings for LXRX

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BooDog maintains that this is still an excellent swing play bio. At least till their next data set.


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LXRX News